What impact do Revlimid® (lenalidomide) and Pomalyst® (pomalidomide) have on the bone marrow?

 

In this week’s video, Brian G.M. Durie explains that even though Revlimid and Pomalyst may reduce white blood cell counts, they do not permanently affect the bone marrow.

BOTTOM LINE:
Revlimid and Pomalyst may reduce white blood cell counts, so stop or adjust dosing accordingly.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org